New perspectives in the treatment of heart failure: The role of SGLT2 inhibitors

Abstract

Heart failure (HF) has been a prevalent chronic disease globally and one of the main causes of mortality historically. A recent study assessed the impact of sodium-glucose cotransporter 2 inhibitors (SGLT2 inhibitors) on the management of HF. It focused on improving health outcomes and the quality of life of patients. The methodology included a systematic review of clinical and observational trials that compared SGLT2 inhibitors with standard treatments and placebos. The efficacy of SGLT2 inhibitors was examined across various patient subgroups, taking into account variables such as renal and cardiovascular function, vascular resistance, and neurohormonal mechanisms. The results showed that SGLT2 inhibitors significantly improved cardiac and renal function. They also reduced mortality and hospitalizations associated with HF. These benefits were observed in both patients with type 2 diabetes and those without this condition. In conclusion, the study confirmed that SGLT2 inhibitors are a valuable therapeutic option for patients with HF. It highlighted the need to include them in treatment strategies and emphasized the importance of expanding research to better understand the mechanisms, efficacy, and safety of SGLT2 inhibitors in HF, thereby guiding future health policies.